Table 1.
Posterior Segment Drug Delivery Systems for the Treatment of Cystoid Macular Edema (CME)
| Drug released | Commercial name | Indication | Administration | Current status | Drug-release duration |
|---|---|---|---|---|---|
| Dexamethasone 0.7mg | Ozurdex | RVO, NIPU, DME | Intravitreal injection (22-gauge aplicator) | FDA approved | 6 months |
| Fluocinolone Acetonide 0.59mg | Retisert | NIPU | Small pars plana incision; Sutured to the sclera. | FDA approved | 2.5 years |
| Fluocinolone Acetonide 0.19mg | Iluvien | Chronic DME | Intravitreal injection (25-gauge aplicator) | FDA approved | 3.0 years |
| Dexamethasone | Cortiject | DME | Intravitreal injection | Phase I study | 6–9 months |
| Triamcinolone acetonide 0.925μg | I-vation | DME | Intravitreal injection (25-gauge aplicator) | Phase 2 suspended | 2 years |
| Triamcinolone acetonide (IBI-20089) | Verisome | DME | Intravitreal injection (30-gauge aplicator) | Phase I | 1 year |
Legends:
RVO – Retinal vein occlusion
NIPU – Noninfectious posterior uveitis
DME – Diabetic macular edema
FDA – Food and Drug Administration